<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7501082\results\search\drug\results.xml">
  <result pre="polymerase Hel, helicase S protein, Spike protein TMPRSS2, Trans-Membrane Protease" exact="Serine" post="Protease-2 TMPRSS4, Trans-Membrane Protease Serine Protease-4 HAT, Human Airway"/>
  <result pre="Spike protein TMPRSS2, Trans-Membrane Protease Serine Protease-2 TMPRSS4, Trans-Membrane Protease" exact="Serine" post="Protease-4 HAT, Human Airway Trypsin-like protease TGN, Trans-Golgi Network"/>
  <result pre="CMK, Chloro-Methyl-Ketone Dec, Decanoyl Phac, Phenyl-Acetyl TTSP, Type II Transmembrane" exact="Serine" post="Proteases family HPV, Human Papillomavirus HBV, Hepatitis B virus"/>
  <result pre="sulphonyl fluoride BHH, BromHexine Hydrochloride PCSK, Pro-protein Convertase Subtilisin/Kexin AMPK," exact="Adenosine" post="Monophosphate-activated Protein Kinase HCoV-NL63, Human Coronavirus â€&quot; NL63 HCoV-229E,"/>
  <result pre="of non-peptidic inhibitors, such as streptamine-based compounds. Upon addition of" exact="guanidine" post="residues, streptamine derivatives mimic the cationic furin cleavage site"/>
  <result pre="Three-dimensional model of TMPRSS2 in complex with the standard inhibitor" exact="camostat" post="mesylate [90]. The catalytic triad (i.e., His296, Asp345, Ser441)"/>
  <result pre="triad (i.e., His296, Asp345, Ser441) and the predicted interactions of" exact="camostat" post="with the active site residues (i.e., Asp187, Asn346, Cys348,"/>
  <result pre="3.2.3 TMPRSS2 inhibitors Alpha-1-antitrypsin (A1AT), 4-(2-aminomethyl)-benzene-sulfonyl fluoride (AEBSF), Camostat mesylate," exact="Nafamostat" post="and Bromhexine hydrochloride are the best experimentally validated inhibitors"/>
  <result pre="inhibitors Alpha-1-antitrypsin (A1AT), 4-(2-aminomethyl)-benzene-sulfonyl fluoride (AEBSF), Camostat mesylate, Nafamostat and" exact="Bromhexine" post="hydrochloride are the best experimentally validated inhibitors of TMPRSS2,"/>
  <result pre="inhibits also the fusion of the mouse hepatitis coronavirus [95]." exact="Bromhexine" post="hydrochloride (BHH) is a drug used as a mucolytic"/>
  <result pre="of the ligand. Asn450 forms two hydrogen bonds with the" exact="anhydrous" post="carbonyl oxygen, with side chain acceptor and backbone acceptor."/>
  <result pre="the TMPRSS2 catalytic triad (i.e., His296 and Ser441) (Fig. 5C)." exact="Nafamostat" post="and Camostat mesylate bind in the same pocket of"/>
  <result pre="(Fig. 5C). The binding energy of TMPRSS2 with Camostat mesylate," exact="Nafamostat" post="and Bromhexine hydrochloride is of âˆ’7.94Â kcal/mol, âˆ’7.21Â kcal/mol,"/>
  <result pre="The binding energy of TMPRSS2 with Camostat mesylate, Nafamostat and" exact="Bromhexine" post="hydrochloride is of âˆ’7.94Â kcal/mol, âˆ’7.21Â kcal/mol, and âˆ’5.96Â"/>
  <result pre="kcal/mol respectively. Similarly, the inhibition constant (Ki) of Camostat mesylate," exact="Nafamostat" post="and Bromhexine hydrochloride are 1.51Â ÂµM, 5.17Â ÂµM and"/>
  <result pre="Similarly, the inhibition constant (Ki) of Camostat mesylate, Nafamostat and" exact="Bromhexine" post="hydrochloride are 1.51Â ÂµM, 5.17Â ÂµM and 43Â ÂµM,"/>
  <result pre="effect in combination with interferon [105]. The antiviral action of" exact="nitric oxide" post="(NO) has been reported for the treatment of several"/>
  <result pre="actual coronavirus pandemia, selected drugs, like favipiravir, amodiaquine, 2â€²-fluoro-2â€²-deoxycytidine, and" exact="ribavirin" post="are not classified as protease inhibitors, but they were"/>
  <result pre="that Î±-ketoamide analogues bind the Mpro more tightly than the" exact="amoxicillin" post="used as control [128]. One of them, synthesized and"/>
  <result pre="âˆ’8.07Â kcal/mol, respectively) with respect to the control shikonin and" exact="lopinavir" post="(around âˆ’5.4Â kcal/mol) [132]. Bonducellpin D from Caesalpinia bonduc"/>
  <result pre="an alkaloid from the seeds of Lepidium sativum, and (iii)" exact="folic acid," post="which all bind tightly the enzyme forming hydrogen bonds"/>
  <result pre="was performed against the SARS-CoV-2 Mpro, giving the glecaprevir and" exact="maraviroc" post="as the best inhibitors [143]. Further, also selected anti-HIV"/>
  <result pre="simeprevir, faldaprevir, and asunaprevir) were docked against SARS-CoV-2 Mpro. Indeed," exact="simeprevir" post="(Fig. 7D), an approved HCV NS3/4A protease inhibitor, seems"/>
  <result pre="fluvastatin may be novel molecules with inhibitory properties. In fact," exact="pitavastatin" post="(Fig. 7E) has a binding energy greater than that"/>
  <result pre="has a binding energy greater than that of protease inhibitors" exact="nelfinavir" post="and lopinavir, reported in the same study [149]. Potential"/>
  <result pre="kcal/mol), even though the best score was found for the" exact="eszopiclone" post="(âˆ’10.0Â kcal/mol) (Fig. 7F) a drug used for the"/>
  <result pre="of insomnia [151]. Further, the antibiotic talampicillin and the anti-psychotic" exact="lurasidone" post="have been identified by virtual screening as potential drugs"/>
  <result pre="similar score of âˆ’6.4Â kcal/mol [153]. Notably, remdesivir, GS-441524 and" exact="entecavir" post="might be multi-target potential inhibitors for both RNA-dependent RNA-polymerase"/>
  <result pre="6.5Â kcal/mol, respectively) while a lower score was found for" exact="chloroquine" post="and hydroxychloroquine with âˆ’5.0Â kcal/mol and âˆ’5.9Â kcal/mol, respectively"/>
  <result pre="respectively) while a lower score was found for chloroquine and" exact="hydroxychloroquine" post="with âˆ’5.0Â kcal/mol and âˆ’5.9Â kcal/mol, respectively [153]. 4.3.1.2.2"/>
  <result pre="activity of baicalin or baicalein is close to that of" exact="chloroquine" post="(EC50Â =Â 2.71Â ÂµM) and hydroxychloquine (EC50Â =Â 4.51Â"/>
  <result pre="Respiratory tract infection [154] Baicalein 2.94 Respiratory tract infection [154]" exact="Chloroquine" post="2.71/5.47 Malaria [155], [162] Hydroxychloroquine 0.7/4.51 Malaria [162], [155]"/>
  <result pre="2.94 Respiratory tract infection [154] Chloroquine 2.71/5.47 Malaria [155], [162]" exact="Hydroxychloroquine" post="0.7/4.51 Malaria [162], [155] Remdesivir 23.15 Ebolavirus [161] Boceprevir"/>
  <result pre="Î¼M, 9.35Â Î¼M, 1.55Â Î¼M, and 1.82Â Î¼M respectively [124]." exact="Dipyridamole" post="binds Mpro through hydrogen bonds and hydrophobic interactions, showing"/>
  <result pre="0.55Â Î¼M) better than other drugs tested, such as the" exact="disulfiram" post="(4.67Â Î¼M), which was taken as positive control for"/>
  <result pre="was taken as positive control for the bioassay [158]. Furthermore," exact="dipyridamole" post="and montelukast sodium showed a global inhibitory function on"/>
  <result pre="as positive control for the bioassay [158]. Furthermore, dipyridamole and" exact="montelukast" post="sodium showed a global inhibitory function on NF-kB signalling"/>
  <result pre="(lopinavir), 2.55Â Î¼M (homorringtonine), and 0.46Â Î¼M (emetine hydrochloride), while" exact="ribavirin" post="and favipiravir showed no inhibition at 100Â Î¼M. Only"/>
  <result pre="compound concentrations and increase inhibition of viral replication [161]. Finally," exact="chloroquine" post="and hydroxychloroquine both inhibit SARS-CoV-2 in cell assays (EC50Â"/>
  <result pre="and increase inhibition of viral replication [161]. Finally, chloroquine and" exact="hydroxychloroquine" post="both inhibit SARS-CoV-2 in cell assays (EC50Â =Â 5.47Â"/>
  <result pre="inhibit SARS-CoV-2 Mpro [166], were employed in clinical trials, namely" exact="lopinavir" post="and ritonavir, which were administered in adults hospitalized with"/>
  <result pre="relatively more severe illness than older children, a trial of" exact="hydroxychloroquine" post="or lopinavir/ritonavir suggested their use in severe pneumonia and"/>
  <result pre="use in severe pneumonia and critically ill children [168]. The" exact="chloroquine" post="and hydroxychloroquine, originally employed for malaria treatment, deserve a"/>
  <result pre="receptor binding. Unfortunately, the clinical data and the effect of" exact="hydroxychloroquine" post="in combination with azithromycin are mostly controversial about their"/>
  <result pre="clinical data and the effect of hydroxychloroquine in combination with" exact="azithromycin" post="are mostly controversial about their efficacy in COVID-19 treatment."/>
  <result pre="azithromycin are mostly controversial about their efficacy in COVID-19 treatment." exact="Hydroxychloroquine" post="and chloroquine have certain limitations and toxicity, especially on"/>
  <result pre="mostly controversial about their efficacy in COVID-19 treatment. Hydroxychloroquine and" exact="chloroquine" post="have certain limitations and toxicity, especially on the heart"/>
  <result pre="heart and eyes. Considering their ocular, cardiac and neuro toxicities," exact="hydroxychloroquine" post="and chloroquine should not be recommended as preventive drugs"/>
  <result pre="eyes. Considering their ocular, cardiac and neuro toxicities, hydroxychloroquine and" exact="chloroquine" post="should not be recommended as preventive drugs for the"/>
  <result pre="35UlrichH.PillatM.M.CD147 as a target for COVID-19 treatment: suggested effects of" exact="Azithromycin" post="and stem cell engagementStem Cell Rev. Rep.16202043444010.1007/s12015-020-09976-732307653 36Mycroft-WestC.J.SuD.LiY.GuimondS.E.RuddT.R.ElliS.MillerG.NunesQ.M.ProcterP.BisioA.ForsythN.R.TurnbullJ.E.GuerriniM.FernigD.G.YatesE.A.LimaM.A.SkidmoreM.A.SARS-Cov-2 spike"/>
  <result pre="docking studies of TMPRSS2 with experimentally known inhibitors Camostat mesylate," exact="Nafamostat" post="and Bromhexine hydrochloride to control SARS-Coronavirus-2., ChemRxiv. (2020), doi:"/>
  <result pre="of TMPRSS2 with experimentally known inhibitors Camostat mesylate, Nafamostat and" exact="Bromhexine" post="hydrochloride to control SARS-Coronavirus-2., ChemRxiv. (2020), doi: 10.26434/chemrxiv.12162360.v1. 93GuttmanO.BaranovskiB.M.SchusterR.KanerZ.Freixo-LimaG.S.BaharN.KalayN.MizrahiM.I.BramiI.OchayonD.E.LewisE.C.Acute-pahse"/>
  <result pre="M. Yousfi, Hispidin and Lepidine E: two natural compounds and" exact="Folic acid" post="as potential inhibitors of 2019-novel coronavirus main protease (2019-nCoVMpro),"/>
  <result pre="Vitro Antiviral Activity and Projection of Optimized Dosing Design of" exact="Hydroxychloroquine" post="for the Treatment of Severe Acute Respiratory Syndrome Coronavirus"/>
 </snippets>
</snippetsTree>
